November 28, 2017/Cancer/News & Insight

New Guidelines Released for Accelerated Partial-Breast Irradiation

Dr. Chirag Shah led development of consensus statement


Cleveland Clinic researcher and radiation oncologist Chirag Shah, MD, led the development of recently updated guidelines for the appropriate and safe use of accelerated partial-breast irradiation (APBI). The guidelines are published online in the journal Brachytherapy.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

APBI is a breast radiation therapy technique in which targeted radiation is delivered, either via brachytherapy (applicator devices or multiple catheters) or through external beam radiation, specifically to the part of the breast where the tumor was removed with a margin without treating the whole breast.

For patients with ductal carcinoma in situ (DCIS) ­and early-stage invasive breast cancer, APBI has been shown to be an alternative to standard whole-breast irradiation, allowing for a reduction in the duration of radiation therapy. The technique, by reducing the amount of normal healthy breast tissue treated with radiation, may also reduce side effects of treatment and improve cosmetic outcomes.

Dr. Shah led a group of physicians appointed by the American Brachytherapy Society to develop a consensus statement of updated guidelines. The new guidelines recommend the technique for a broader group of patients by allowing younger patients to be eligible as well as all patients with DCIS who meet the other criteria. The authors’ consensus is that the appropriate candidates for APBI include:

  • patients aged 45 years or older
  • all invasive histologies and ductal carcinoma in situ
  • tumors 3 cm or less
  • node negative
  • estrogen receptor positive or negative
  • no lymphovascular space invasion
  • negative margins

“The updated guidelines support clinicians by offering them the ability to appropriately select patients for APBI, and additionally by providing them with data that supports and assesses the strength of the various APBI techniques,” says Dr. Shah. “These guidelines allow for the selection of patients who can finish radiation treatment in one week or less, compared to the traditional period of three to six weeks, and potentially a reduction in side effects depending on the APBI technique.”

The previous APBI guidelines, also led by Dr. Shah, were developed in 2013. Since then, results from newly published randomized trials, including RAPID, IMPORT LOW, University of Florence, ELIOT and TARGIT-A, have necessitated an update to the guidelines.

“As the trials have been published, we’ve updated our thinking about APBI and definitions of standards of care,” says Dr. Shah. “The consensus statement further validates the clinical choices we’ve made for our patients, and I am happy to see this modality available to a broader range of patients.”


Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

October 18, 2023/Cancer/News & Insight
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

August 31, 2023/Cancer/News & Insight
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023/Cancer/News & Insight
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust